Cassava Sciences Inc SAVA shares rallied over 97% today in the regular and after-hours sessions.
What Happened: The upwards movement was an extension from a day ago when shares rose 150% after the company announced the results of an interim analysis of its lead drug candidate for Alzheimer's disease — simufilam.
The clinical-stage biotechnology company said that both cognition and behavior scores improved, without any safety issues after patients were administered six months of treatment with simufilam.
Why It Matters: The company is also developing PTI-125 — an experimental biomarker diagnostic — that can detect Alzheimer's disease with a blood test.
Price Action: Cassava Sciences shares closed 58.64% higher at $87.95 on Wednesday and rose nearly 38.7% in the after-hours session to $122.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
